Omalizumab biosimilar (Curateq Biologics)

N/A

Report date: 2024/09/14 16:39:42

Base Information

Drug NameOmalizumab biosimilar (Curateq Biologics)
Drug Alias NameBP11BP-11
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsChronic Urticaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCuraTeQ Biologics Pvt Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A